Engineered Lactococcus lactis delivering soluble PD-1 modulates epithelial PD-L1 signaling and mucosal T-cell immunity in colorectal cancer
Immune checkpoint inhibitors show limited efficacy in colorectal cancer (CRC), and the mucosal immune mechanisms contributing to this limited response remain incompletely understood. Here, we evaluated the immunopharmacological effects of orally delivered soluble PD-1 using an engineered Lactococcus lactis strain, LL-sPD-1, in CRC models. LL-sPD-1 was designed to deliver the bioactive extracellular domain of PD-1 to the intestinal mucosa and showed good tolerability after oral administration. In both subcutaneous and orthotopic CRC mouse models, LL-sPD-1 inhibited tumor growth and prolonged survival. Under the dosing and experimental conditions tested, its antitumor activity was comparable to that of systemic anti-PD-L1 antibody treatment. To explore the mucosal cellular context associated with this activity, we examined PD-L1 expression in intestinal epithelial cells (IECs) from CRC patients and adenoma controls. PD-L1-positive IECs were more frequent in CRC tissues, and tumor-conditioned medium increased PD-L1 expression in IECs in vitro. Tumor-conditioned IECs were associated with reduced T-cell antitumor activity, which was partially restored by soluble PD-1. In tumor-bearing mice, LL-sPD-1 treatment was accompanied by reduced epithelial PD-L1 detection, fewer PD-1 + CD8 + T cells and more IFN-γ + CD8 + T cells in the lamina propria. Intestinal PD-L1 knockdown produced a similar antitumor effect, without further enhancement by LL-sPD-1, suggesting that intestinal PD-L1-related pathways may contribute to the response. These findings suggest that oral LL-sPD-1 modulates mucosal PD-1/PD-L1 signaling and supports further investigation of epithelial checkpoint targeting in CRC immunotherapy.
Authors
- Hanlin Zhang (ORCID: https://orcid.org/0000-0001-9353-6071)
- Wanzhu Jin (ORCID: https://orcid.org/0000-0002-5860-2958)
- Gang Sun (ORCID: https://orcid.org/0000-0001-8594-557X)
- Wenzhe Li (ORCID: https://orcid.org/0000-0003-3898-5602)
- Meng Dong (ORCID: https://orcid.org/0009-0003-2787-1877)
- Lu Han (ORCID: https://orcid.org/0000-0002-1753-0732)
- Jie Zhang (ORCID: https://orcid.org/0009-0004-5173-9996)
- Zhi Zhang
- Yuanyuan Huang
- Yujian Zhang
- Zizhen Zhang
- Zhi Peng
Institutions
- Chinese Academy of Sciences (CN)
- Chinese PLA General Hospital (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Henan University of Engineering (CN)
- Ministry of Education (ET)
- University of Chinese Academy of Sciences (CN)
- Institute of Zoology (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1016/j.intimp.2026.117708
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00